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Azidothymidine (AZT) is a synthetic, chain-terminating nucleoside analog used to treat
HIV-1 infection. While AZT is not actively transported across the blood brain barrier, it
does accumulate at high levels in cerebrospinal fluid, and subsequently diffuses into
the overlying parenchyma. Due to the close anatomical proximity of the neurogenic
niches to the ventricular system, we hypothesize that diffusion from CSF exposes
neural stem/progenitor cells and their progeny to biologically relevant levels of AZT
sufficient to perturb normal cell functions. We employed in vitro and in vivo models
of mouse neurogenesis in order to assess the effects of AZT on developing and adult
neurogenesis. Using in vitro assays we show that AZT reduces the population expansion
potential of neural stem/progenitor cells by inducing senescence. Additionally, in a
model of in vitro neurogenesis AZT severely attenuates neuroblast production. These
effects are mirrored in vivo by clinically-relevant animal models. We show that in utero
AZT exposure perturbs both population expansion and neurogenesis among neural
stem/progenitor cells. Additionally, a short-term AZT regimen in adult mice suppresses
subependymal zone neurogenesis. These data reveal novel negative effects of AZT on
neural stem cell biology. Given that the sequelae of HIV infection often include neurologic
deficits—subsumed under AIDS Dementia Complex (Brew, 1999)—it is important to
determine to what extent AZT negatively affects neurological function in ways that
contribute to, or exacerbate, ADC in order to avoid attributing iatrogenic drug effects
to the underlying disease process, and thereby skewing the risk/benefit analysis of AZT
therapy.
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Introduction
AZT (3′-azido-3′-deoxythymidine; AZT, zidovudine or Retrovir) is a synthetic, chain-terminating
thymidine analog in which the 3′-hydroxyl group is replaced with an azido group. AZT is con-
verted intracellularly into active AZT-triphosphate (AZT-PPP) which competes with the nat-
ural substrate—deoxythymidine triphosphate (dTTP)—for incorporation into elongating viral
DNA chains by HIV reverse transcriptase (RT). Once added to a DNA chain, AZT pre-
vents further addition of nucleotides by impeding 5′-3′ phosphodiester linkages via its 3′-
azido group. AZT has been used in the treatment of HIV infection, alone, or in combination
with other antiviral agents as a part of Highly Active Antiviral Therapy (HAART). The
present recommendations for adult patients call for 500–600mg AZT/day. This dose is approx-
imately equivalent to 10mg/kg/day, and results in a steady-state serum AZT concentration
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of 0.8µM(Fletcher et al., 2002). AZTmonotherapy is also recom-
mended to reduce vertical transmission of HIV-1 from mother
to child during pregnancy, parturition, and/or breastfeeding.
In a non-breastfeeding population AZT monotherapy has been
shown to reduce mother-to-child HIV transmission rate from
25.5 to 8.3% (Connor et al., 1994). On the other hand, AZT is still
classified in Pregnancy Category C by the Food andDrug Admin-
istration due to the potential risks to the fetus (Walker et al., 2007;
Durand-Gasselin et al., 2008; Read et al., 2008; Foster et al., 2009).
Although AZT is considered to be effective in reducing viral
load, numerous studies show significant adverse side-effects such
as bone morrow suppression, cardiomyopathy, hepatotoxicity,
neuropathy, andmitochondrial damage (Ayers et al., 1996; Chow
et al., 1997; Zhang et al., 1998; Diwan et al., 1999; Anderson
et al., 2003; Lee et al., 2003; Lewis, 2003; Lewis et al., 2003, 2004;
Lai et al., 2004; Torres et al., 2007). Indeed, abnormal mito-
chondrial respiratory chain complex activity, alterations in brain
morphology, neurological anomalies, cognitive impairments, and
episodes of seizures in children exposed to AZT in utero and
after birth is reported (Blanche et al., 1999, 2006). A greater
than expected proportion of birth defects was shown in the cen-
tral nervous system (CNS), heart, and chromosomes of children
exposed to AZT in utero (Newschaffer et al., 2000). Congeni-
tal CNS anomalies such as anencephaly, microencephaly, and
corpus callosum agenesis were reported following prenatal AZT
administration (Joao et al., 2010).
Experimental animal models of in utero AZT treatment sup-
port the clinical human findings. AZT was detected in DNA
of fetal liver, lung, heart, skeletal muscle, brain, testis, and
placenta in Macaca mulatta exposed to AZT during gestation
(Poirier et al., 1999; Slikker et al., 2000). Alterations of oxidative
phosphorylation complexes were shown in mitochondria of Ery-
throcebus patas brain, heart, andmuscle (Ewings et al., 2000; Ger-
schenson and Poirier, 2000; Gerschenson et al., 2000), and DNA
attrition was shown in both monkeys and mice exposed to the
drug in utero (Olivero et al., 1997). Furthermore, telomeric short-
ening was observed in a variety of tissues, including the brain,
lung, and liver of transplacentally-treated mice (Olivero, 2007).
Offspring of AZT-treated rodents were shown to have neurobe-
havioral abnormalities, suggesting that AZT perturbs CNS devel-
opment; these abnormalities include deficits in: motor responses;
investigative, exploratory, and social behavior; and learning and
spatial tasks (Petyko et al., 1997; Busidan and Dow-Edwards,
1999; Calamandrei et al., 1999a,b, 2002a,b; Rondinini et al., 1999;
Venerosi et al., 2000, 2003, 2005; Melnick et al., 2005). Especially
relevant to our present study, Busidan et al. (2001) have shown
that a single dose of 150mg/kg AZT delivered to pregnant rats
on gestational day 20 leads to a heterogeneous distribution of
AZT in fetal brains with relatively greater amounts present in the
periventricular area. Despite the extensive literature pertaining
to AZT toxicity in a variety of systems and cell types, surprisingly
little attention has been paid to the potential deleterious effects of
AZT administration on neurogenesis.
In mammals, neural stem cells continue to produce new neu-
rons throughout life. Specifically, the subgranular zone (SGZ) of
the dentate gyrus and the forebrain subependymal zone (SEZ) are
regions where new neurons are produced for the hippocampus
and olfactory bulb (OB), respectively. SEZ neural stem/ progen-
itor cells are located immediately subjacent to the ependymal
lining of the anterolateral wall of the lateral ventricle, and there is
evidence that stem cells in this region have a ciliated endfoot that
intercalates among the ependymal cells to make direct contact
with cerebrospinal fluid (CSF) in the ventricle (Mirzadeh et al.,
2008; Tavazoie et al., 2008). Such an anatomical arrangement
makes it extremely likely that passive diffusion of AZT from the
CSF will bring the drug into contact with both SEZ stem cells, and
their more fate-restricted progeny that maintain an intimate rela-
tionship with the anterior extension of the lateral ventricle as they
migrate through the rostral migratory stream to the OB. Like-
wise, the mouse dorsal hippocampus sits essentially within the
posteromedial aspect of the lateral ventricle, and also forms part
of the posterosuperior border of the third ventricle. The dentate
gyrus itself is located fairly superficially, again making it likely
that AZT will diffuse to the site of hippocampal neurogenesis in
the SGZ.
The in vivo neural stem cell has an in vitro correlate known
as the neurosphere. Neurospheres are multipotent clones derived
from single neural stem cells. Neurospheres consist of neural
stem cells that undergo a few rounds of symmetric division, and
more fate-restricted progenitors that result from extensive asym-
metric division of the stem cells (Deleyrolle and Reynolds, 2009).
Furthermore, neurosphere abundance, or yield, in vitro has been
shown to mirror increases and decreases in levels of in vivo neu-
rogenesis (Doetsch et al., 1999). Finally, neural stem/progenitor
cells (NSPCs) within the rodent SEZ and hippocampus have been
shown to maintain relatively high levels of telomerase activity
throughout life (Caporaso et al., 2003), perhaps rendering them
uniquely susceptible to AZT toxicity. In this study, we aimed to
determine whether clinically relevant AZT regimens perturb nor-
mal functioning of NSPCs in developing and adult mouse brain.
We hypothesize that the relatively superficial location of NSPC
niches of both SGZ and SEZ subjacent to the ventricular lining-
will expose these germinal matrices to harmful levels of AZT
from the CSF.
Materials and Methods
Animals
C57BL/6 mice were used for all in vivo model systems. Four
month old males were used for studies of adult neurogenesis.
In utero studies were performed on 4 month old pregnant dams,
and male and female pups were pooled for analysis. All animals
were housed at the University of Florida’s Department of Animal
Care Services in compliance with Institutional Animal Care and
Use Committee (IACUC) regulations.
Generation and Expansion of Multipotent
Astrocyte Stem Cell (MASC) Cultures
Multipotent astrocytic stem cell (MASC) cultures were gener-
ated as described (Laywell et al., 2000; Marshall et al., 2008).
Briefly, mouse pups were decapitated under hypothermic anes-
thesia according to institutional veterinary protocol. SEZ tissue
surrounding the lateral ventricles was dissected using a sterile
razor blade, and the tissue was minced and placed in ice-cold
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DMEM/F12 medium with N2 supplements (Gibco BRL, 17502-
048), (N2 Media), containing 1X antibiotic-antimycotic (Invitro-
gen, 15240-062) for 15min. After centrifugation at 400 × g for
5min, the tissue was incubated in 0.25% Trypsin/EDTA solu-
tion (Atlanta Biologicals; B81310) for 5–7min at 37◦C. Trypsin
activity was inhibited by adding a bolus of N2 media contain-
ing 5% fetal bovine serum (FBS; Atlanta Biologicals). The tissue
was triturated into a single-cell slurry using fire-polished Pasteur
pipettes of sequentially smaller diameter. Cells were washed in
N2 media and pelleted by centrifugation at 400 × g for 5min
before being re-suspended in neural growth medium consisting
of N2 medium, 5% FBS, 20 ng/mL recombinant human epider-
mal growth factor (rhEGF, Sigma-Aldrich, St. Louis, MO; E9644),
and 10 ng/mL fibroblast growth factor 2 (bFGF, Sigma-Aldrich,
F0291). The single-cell suspension was then plated onto tissue
culture flasks (T25) and incubated at 37◦C in 5% CO2. After two
days of incubation, the neural growthmediumwas refreshed, and
cells were supplemented every other day with EGF and FGF (10
and 20 ng/mL final concentration, respectively) until the primary
culture reached confluence.
Inducible Neurogenesis
Confluent primary MASCs were trypsinized and passaged at a
density of 17,500 cells/cm2 neural growth medium and sup-
plemented as above until confluency was established (typically
7–10 days). To induce differentiation, passage 1 MASC were
plated (17,500 cells/cm2) onto glass coverslips coated with poly-
L-ornithine (10µg/mL, Sigma, P4957), and were supplemented
every other day with 20 ng/mL EGF and 10 ng/mL bFGF. Four
days after plating the growth medium was replaced with serum-
and growth factor-free N2 medium. This withdrawal of serum
and growth factors induces a burst of neuroblast production
from the MASC culture. Forty eight hours after withdrawal
of neural growth medium, the cells were either fixed with 4%
paraformaldehyde in PBS for subsequent immunocytochemical
analysis, or were trypsinized and quantified with a Z2 Coulter
Counter (Beckman Coulter, Fullerton, CA).
Immunocytochemistry
Paraformaldehyde-fixed cells were prepared for immunocyto-
chemistry by washing with phosphate buffered saline (PBS) and
blocking at room temperature (RT) for 30–60min in PBS con-
taining 0.01% Triton X-100 (PBSt) and 10% FBS. Primary anti-
bodies were applied overnight in PBSt containing 10% FBS
with moderate agitation at 4◦C. Residual primary antibody was
removed by washing with PBS twice, and secondary antibod-
ies were applied at RT for 1 h in PBSt containing 10% FBS.
Residual secondary antibodies were removed by washing with
PBS. For nuclear counterstaining, the coverslips were mounted
onto glass slides and layered with Vectashield mounting medium
containing 4′, 6-diamidino-2-phenylindole (DAPI; Vector, H-
1200). Cells were analyzed and photographed by using a Leica
DMLB upright epifluorescence microscope (Leica Microsystems
AG, Wetzlar, Germany) with a Spot RT color CCD camera
(Diagnostic Instruments). For quantification of stained cells,
a minimum of 10 randomized fields were selected at 20X
magnification.
Neurosphere Culture
Neurospheres (NS) were generated according to methods previ-
ously described by our laboratory (Laywell et al., 2002; Marshall
et al., 2006). Briefly, single-cell dissociates of neonatal SEZ (as
described above) were plated under anchorage withdrawal in low
attachment flasks (Nalge Nunc International, 136196) at a den-
sity of 10,000 cells/mL. The medium consisted of NeuroCult R©
NSC Proliferation Medium (Mouse) consisting of NeuroCult R©
NSC Basal Medium and NeuroCult R© NSC Proliferation Supple-
ment (Stem Cell Technologies, 05700 and 05701) supplemented
with EGF (20µg/mL), FGF (10µg/mL), and heparin (2µg/mL,
Stem Cell Technologies, 07980). Cultures were incubated at 37◦C
in 5% CO2 for 7 days, at which time the number and diameter
of NS were assessed and classified using Spot Advanced digital
capture software.
Neural Colony Forming Cell (NCFC) Assay
The neural colony forming cell assay was performed as described
by Azari et al. (2011). A single-cell suspension from neona-
tal SEZ was plated in 35mm culture dishes at 250 cells/cm2 in
a serum-free, semi-solid collagen media containing NeuroCult
NCFC serum-free medium without cytokines (Stem Cell Tech-
nologies, 05720), NeuroCult Proliferation Supplement, hEGF
(20µg/mL), hbFGF (10µg/mL), and heparin (2µg/l) for 3 weeks
at 37◦C in 5% CO2. Cultures were supplemented with Complete
Replenishment Medium consisting of NSC Basal Medium, NSC
Proliferation Medium, hEGF (20µg/mL), hbFGF (10µg/mL),
and heparin (2µg/mL) once a week. Colonies were classified
into four categories based on diameter (<0.5mm, 0.5-mm,
1–2mm, ≥2mm) by scanning a gridded scoring dish at 4X
magnification.
Senescence-Associated β-Galactosidase
Labeling
X-Gal cytochemical staining at pH 6.0 was performed as
described (Dimri et al., 1995). Briefly, cells were fixed for 5min
in 0.2% glutaraldehyde in PBS. After two washes with PBS,
cells were incubated in SAβGal staining solution containing:
1mg/mL 5 bromo-4-chloro-3-indolyl B-D galactoside (X-Gal),
40mM sodium citrate pH 6.0, 5% dimethylformamide, 5% potas-
sium ferrocyanide, 5mM ferricyanide, 150mM sodium chloride
and 2mMmagnesium chloride for 6 h at 37◦C. Cells were washed
with PBS, and counterstained with Vectashield + DAPI. The per-
centage of positive SAβGal+ cells was counted on 10 random
fields of triplicate samples.
In Vitro Drug Treatment
AZT (TCI America, A2052) was dissolved in N2 medium, fil-
tered through 0.22µmmesh, and stored in ready-to-use aliquots
at −20◦C. Based on the literature review, AZT was added to cul-
tures at a final concentration of 0–60µM, which corresponds to
the range of doses administered in human patients (Chiu and
Duesberg, 1995). Exposure times ranged from 2 to 48 h, after
which the medium was replaced with fresh medium without
AZT. Control and treated cultures received the same number of
medium changes.
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In Vivo AZT Administration
Presently, the U.S. Food and Drug Administration (USFDA) rec-
ommends AZT administration of 600mg/day, which is about
10mg/kg for adults. The recommended pediatric dosage is 24–
600 mg/day. In order to equate mouse and human doses, we used
mg/m2 conversion factors based on these USFDA recommenda-
tions. Accordingly, a 10mg/kg dose, which is 600mg AZT/day,
administered to humans with 1.1710 m2 body surface area would
be equal to a 143mg/kg dose administered to a mouse with 25 g
body weight and 0.007 m2 body surface area. Adult, male, C57
BL/6 mice (n = 4 per group) received daily i.p. injections of
AZT at 0, 1, 10, 20, and 100mg/kg/day for 2 weeks. On the
day following the last AZT injection, all animals received four
i.p. injections of the S-phase marker, 5-bromo-3′-deoxyuridine
(BrdU;100mg/kg), every 2 h. Animals were sacrificed 1week after
the final BrdU injection.
In Utero AZT Administration
C57BL/6 pregnant dams (n = 4 per group) received two sub-
cutaneous injections of 200 ul of 0.9% saline containing 0 and
250mg/kg/day AZT during the last 7 days of gestation (E12-E18;
final 37% of gestation period), and for 3 days postpartum in order
to expose the pups to AZT via nursing. MASC and neurospheres
were generated from the SEZ of litters exposed to AZT.
Immunohistochemistry
Adult animals were transcardially perfused with 4%
paraformaldehyde in PBS. Fixed brains were cryoprotected
by immersion in 30% sucrose for 18–24 h. Using a freezing
microtome, the hemispheres were cut exhaustively through
the sagittal plane at 40µm, and sections were stored at -20◦C
in cryoprotectant solution consisting of 50% 0.1M PO4, 25%
glycerol, 25% polyethylene glycol. BrdU immunohistochemistry
was performed as previously described (Laywell et al., 2005).
Briefly, brain sections were washed in PBS and incubated in
2xSSC:formamide (1:1) at 65◦C for 2 h. After a wash in 2xSSC,
sections were incubated in 2N HCl at 37◦C for 30min. Finally,
sections were rinsed in 0.1M borate buffer at room temperature
for 10min and processed for the standard immunofluorescence
detection of BrdU with a rat anti-BrdU antibody (Abcam,
Cambridge, MA, ab6326). Sections were co-labeled with an
antibody against NeuN, a nuclear antigen specific to mature
neurons that delineates the anatomical regions of interest for
these studies (i.e., SEZ and hippocampal dentate gyrus). BrdU+
cells were quantified in the SEZ and hippocampal dentate gyrus
of each animal using a random 1-in-6 sample of serial sections
from the entire left hemisphere. Each series consisted of 17–20
brain sections, depending on total brain size as well as variations
inherent to the blocking and sectioning processes. In each section
that contained the region of interest, a single focal plane was
identified, and only BrdU+ cells within that plane were included
for quantification purposes. Due to sectioning thickness and
antibody penetration characteristics, the sections used in our
analyses contained two distinct focal planes, one of which was
excluded in order to avoid potentially counting the same cell
twice. The total number of BrdU+ cells present in each sample
set was then multiplied by the sampling ratio of 6 to establish an
estimate of the total relative number of BrdU+ cells in the region
of interest of one hemisphere.
Statistics
All in vitro experiments were conducted in triplicate on iden-
tical sister cultures (N = 3). In vivo experiments were con-
ducted with four animals in each group (N = 4). All statis-
tical analyses were performed with GraphPad Prism 4.02 (San
Diego, CA). Data were subjected to either One-Way ANOVA
with the Tukey–Kramer or Dunnet’s Multiple Comparison Test
for multiple-group comparisons, or unpaired Student’s T-test for
two-group comparisons. Asterisks (∗) indicate groups with sta-
tistically significant differences (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p <
0.001).
Results
AZT Reduces MASC Population Expansion
MASC culture enables us to investigate the chain of events
involved in proliferation and differentiation of neurogenic
FIGURE 1 | AZT reduces MASC population expansion. (A) Primary
MASCs exposed to a single 7 day pulse of 30µM AZT show a significant
decrease in population expansion over the first and second passages (1stP,
2ndP). By the third passage (3rdP), treated cells recover and slightly exceed
the expansion of untreated cells, although this difference was not maintained,
and control and treated groups equilibrated at later passages (not shown). (B)
Naïve 1stP, 2ndP, and 3rdP MASCs exposed to a single 7 day pulse of 30µM
AZT show that “older” cells (increased in vitro passage) are substantially more
vulnerable to the suppressive effects of AZT than “younger” cells. Unpaired
t-test of significance; N = 3 for all groups; ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p < 0.001. Error bars represent standard deviation.
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FIGURE 2 | AZT reduces neurosphere size. Single-cell dissociates of
primary postnatal SEZ form neurospheres within 10 days in vitro. AZT (0, 0.3,
or 30µM) was added to the culture medium for 1, 3, or 10 days beginning on
in vitro day 1, and neurospheres were quantified and measured on in vitro
day 11. (A) Representative untreated control neurospheres on day 11. (Inset
in A) Representative day 11 neurospheres treated with 30µM AZT for 3
days. AZT reduces neurosphere size in both a concentration- and
time-dependent manner (B–D). With increasing exposure time and
increasing dose there is a shift in the distribution of neurosphere sizes. While
total neurosphere number remains constant among the control and treated
groups, AZT induces an increase in smaller neurospheres at the expense of
larger neurospheres. Notice the increasing height of the yellow bar (small
neurospheres with a diameter less than 40µM) and a corresponding
decrease in the height of the blue and green bars (medium and large
neurospheres, respectively). The cultures treated with 0.3µM AZT show a
trend toward smaller neurospheres that does not reach statistical
significance compared to untreated controls. Cultures treated with 30µM
AZT show clearly significant loss of medium and large neurospheres at days
3 and 10. One-Way ANOVA, Dunnett’s Multiple Comparison Test of
significance; N = 3 for all groups; ∗p < 0.05. Asterisks indicate a significant
difference as compared to the corresponding size range of neurospheres in
matched, untreated cultures. Error bars represent standard deviation.
stem/progenitor cells. In order to assess the possible adverse
effects of AZT on neurogenic stem/progenitor cell expansion,
primary MASC were treated with a single-pulse of 30µM AZT,
and growth was analyzed sequentially over three passages. This
single-pulse exposure of primary MASC cells to AZT causes a
significant decrease in the expansion potential of the progeny
over the next two passages (Figure 1). First and second passage
AZT-treated cells show a significant reduction in cell numbers
compared to their untreated controls (Figure 1A). By the third
passage AZT-treated cells have recover and slightly exceed con-
trol levels, though control and treated cultures equilibrate at later
passages (not shown). These results indicate that the suppres-
sive effect of single-pulse AZT on population expansion is not
permanent.
Interestingly, later-passage (“older”) MASC are more suscep-
tible to the suppressive action of single-pulse AZT, and this effect
is progressively stronger with increasing in vitro “age.” Thirty
µM AZT applied at the time of passaging to naïve first, second
and third passage MASC causes a more robust suppression of
population expansion as compared to application at the time of
initial primary cell plating (Figure 1B).
AZT Reduces Neurosphere Size
The neurosphere (NS) assay is a second cell culture system
that allows us to investigate the effects of AZT on neurogenic
stem and progenitor cells (Deleyrolle and Reynolds, 2009). NS-
forming cells were treated the day after plating with a single
pulse of AZT at either 0.3 or 30µM. AZT remained in the cul-
ture medium for 1, 3, or 10 days (Figure 2). Quantification of
NS number and size on day 10 reveals that there is no differ-
ence in total NS number between untreated controls and either
of the AZT-treated groups; however, AZT does cause a significant
reduction in neurosphere size in both a time- and concentration-
dependent manner as compared to untreated NS-forming cell
controls (Figures 2B–D). While total NS number among the
groups does not differ, there is a progressive reduction in the
number of large NS (>80µM diameter, green bars), and a corre-
sponding increase in the number of small NS (<40µMdiameter,
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FIGURE 3 | AZT perturbs neural colony formation by both neural stem
cells and neural progenitor cells. (A) Dissociated primary neurosphere cells
were cultured in the Neural Colony-Forming Cell Assay in the presence of 0.3
or 30µM AZT. After 21 days in vitro, colonies were classified into one of four
categories based upon diameter. (B) AZT at both concentrations causes a
decrease in the size of neural colony formation by both stem cells (≥2mm)
and progenitor cells (<2mm). (C) Pre-treatment of primary NS with 0.3 or
30µM AZT prior to dissociation into the NCFC Assay does not affect colony
formation as severely as direct AZT application after dissociation. Here, 30µM
AZT pre-treatment disturbs the formation of colonies derived from neural
progenitor cells (<2mm), but does not decrease colonies derived from stem
cells (≥2mm). P, pre-treatment; One-Way ANOVA, Dunnett’s Multiple
Comparison Test of significance; N = 3 for all groups; ∗∗p < 0.001. Error bars
represent standard deviation. NCFC frequency (%) = (number of colonies/total
cells plated) (100).
yellow bars) and medium NS (40–80µM diameter, blue bars)
in cultures treated with AZT. This effect is stronger in the cul-
tures receiving 30µMAZT, and becomes more pronounced with
increasing AZT application time (i.e., notice the emergence of
exclusively small neurospheres in the 10 day), 30µM AZT cul-
tures (Figure 2D). The fact that NS frequency is not altered sug-
gests that AZT does not directly interfere with the survival of
NS-forming cells. However, NS diameter is used as a metric of
the capacity for self-renewal (Marshall et al., 2007), and the clear
reduction in NS size suggests an AZT-mediated perturbation of
normal proliferative capacity.
AZT Perturbs Neural Colony Formation by Stem
and Progenitor Cells
The Neural Colony Forming Cell (NCFC) assay allows us to dis-
tinguish between and quantify neural stem cell (NSC) vs. neural
progenitor cell (NPC) frequency. NSCs, having higher prolifer-
ative potential, form colonies ≥2mm in diameter in semi-solid
medium. On the other hand, more restricted neural progenitor
cells (NPC) lack the extensive self-renewal of NSC, and therefore
form colonies that are always <2mm in diameter under these
culture conditions (Deleyrolle et al., 2011). In order to deter-
mine if AZT affects the ability of primary NSC and/or NPC
to form colonies, we exposed dissociated primary NS (contain-
ing a mixture of NSC and NPC) to a single pulse of either 0.3
or 30µM AZT. After 21 days in culture, colonies were clas-
sified into four categories based on diameter (Figure 3). Our
data show (Figure 3B) that single-pulse AZT exposure causes
a concentration-dependent decrease in the formation of neural
colonies derived from both NPC (<2mm in diameter) and NSC
(>2mm in diameter). In order to further examine potential dif-
ferential effects of AZT on NSC vs. NPC we exposed primary
neurospheres to a single pulse of 0.3 and 30µM AZT before dis-
sociation and re-plating in the NCFC assay. Our results show that
pre-treatment with 30µM AZT disturbs formation of colonies
smaller than 2mm in diameter, colonies derived from NPCs, but
not colonies larger than 2mm which are colonies derived from
NSCs (Figure 3C). This result suggests the NPC may be more
at risk for the suppressive effects of AZT, since the “window” of
susceptibility to exposure seems to be longer than that for NSC.
AZT Attenuates Inducible Neurogenesis from
MASC
MASC can be induced to generate large numbers of neurob-
lasts upon withdrawal of serum and mitogens (Scheﬄer et al.,
2005). MASC isolated from SEZ were grown to confluence on
an adhesive surface in the presence of serum and the mitogens
EGF and bFGF. Twenty four hours after withdrawal of serum
and mitogens, MASC generate characteristic rosettes of cell clus-
ters consisting of B-III-tubulin+ neuroblasts (Figures 4A,B). To
assess the effect of AZT on this model of inducible neurogenesis,
we exposed MASC to AZT at the time of induction (serum and
mitogen withdrawal). We show that a single 48 h-pulse of AZT
(0.3–60µM) at the time of withdrawal causes a mild decrease in
total cell number, but a severe reduction in neuroblast induction
(Figures 4C,D). Total cell number was reduced approximately
10–25% in the treated cultures, while neuroblast induction was
reduced by 50–90% as compared to untreated controls.
In order to examine the minimum duration and dosage
of AZT exposure required to perturb inducible neurogenesis,
MASC were treated with for 2, 8, or 24 h with AZT (0.03–3µM)
at the time of serum and mitogen withdrawal (Figure 5). We
show that even a 2 h exposure to the lowest concentration of AZT
significantly suppresses neuroblast formation (Figures 5A–C).
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FIGURE 4 | AZT Attenuates Inducible Neurogenesis from MASC.
Serum and mitogen withdrawal for 48 h induces neurogenesis from MASC
cultures. Representative immunofluorescence images show control (A) and
induced (B) MASC cultures immunolabeled for β-III tubulin (red) and DAPI
(blue). Inset in (B) reveals the morphology of newly-generated, β-III tubulin+
neuroblasts at higher magnification. (C,D) A single 48 h-pulse of 0.3, 3, 30,
or 60µM AZT initiated at the time of withdrawal causes a mild decrease in
total cell number, but a severe reduction in the number of induced
neuroblasts. Treated cultures contain 75–90% as many total cells as
untreated controls (panel C, left four bars). However, treated cultures contain
only 10–50% as many β-III tubulin-positive neuroblasts as control cultures
(panel C, right four bars). Expressed as a percentage of total cells (D),
neuroblasts in untreated induced cultures comprise about 45% of all cells,
while in AZT-treated induced cultures neuroblasts represent from 15%
(0.3µM) to less than 2% (30 and 60µM) of total cells. One-Way ANOVA,
Dunnet’s Multiple Comparison Test of significance; N = 3 for all groups;
Asterisk indicates values significantly different from untreated controls,
∗p < 0.01. Error bars represent standard deviation.
On the other hand, MASC treated with the same concentration
range of AZT for 3 days prior to supplement withdrawal do not
show a much less dramatic response (Figure 5D), suggesting that
AZTmust be present at the time of induction in order to exert an
inhibitory effect upon neuroblast generation.
AZT Induces a Senescence Phenotype in MASC
Senescence associated B-galactosidase (SA-B-Gal) activity has
been used as a biomarker to detect senescent cells in vitro and
in vivo (Dimri et al., 1995). In order to determine if AZT causes
an increase in senescence associated B-galactosidase activity, we
exposed neurosphere-forming cells to a single pulse of 30µM
AZT 24 h after plating. Subsequently, neurospheres formed from
these treated cells were dissociated and assayed for SA-B-Gal
expression (Figures 6A,B). Our results show an approximate 15-
fold increase in SA-B-Gal expression in the AZT-treated neuro-
sphere cells as compared to untreated controls (Figure 6C; 2 vs.
33%).
In addition, we also examined senescence phenotype in
AZT-treated MASC. After a single 24 or 48 h pulse of 0.3
or 30µM AZT MASC were assayed for SA-B-Gal expression
(Figures 6D,E). We find that there is no significant difference
in SA-B-Gal expression between untreated controls and AZT-
treated MASC with either dose after 24 h of exposure (Figure 6F,
gray bars). However, at 48 h of exposure, both 0.3 and 30µM
AZT is associated with upregulation of SA-B-Gal as compared
to untreated controls (Figure 6F, green bars).
In Vivo AZT Administration Reduces Proliferation
in Adult Germinal Zones
Given that AZT is classified as a Rank 1 drug with respect to
CNS penetration, we aimed to determine if in vivo administra-
tion of AZT alters the proliferation potential of NSPCs within the
persistent neurogenic niches of the vertebrate brain. We admin-
istered AZT to adult male mice at 0, 20, or 100mg/kg/day via
daily intraperitoneal injection for 2 weeks. On the day follow-
ing the last AZT injection, all animals received 4 BrdU injections
(100mg/kg) at 2 h intervals. After an additional week the animals
were sacrificed and their SEZ and dentate gyrus were processed
for BrdU immunohistochemistry (Figures 7A,B). Our results
show that 2 week administration of low dose AZT (20mg/kg/day)
does not alter the number of BrdU+ cells present in either the
dentate gyrus or the SEZ (Figure 7C). However, the moderate
dose of 100mg/kg/day is associated with reduced numbers of
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FIGURE 5 | Short, low-dose AZT exposure at the time of withdrawal is
sufficient to perturb inducible neurogenesis. At the initiation of serum
and mitogen withdrawal MASCs were treated with a single pulse of 0.03,
0.3, or 3µM AZT for 2, 8, or 24 h (A–C, respectively). All AZT doses suppress
neuroblast induction in a dose- and time-dependent manner. Even the lowest
concentration of AZT, 0.03µM, applied for only 2 h at the time of serum and
mitogen withdrawal significantly decreases neuroblast formation compared
to the control group. In contrast, AZT pre-treatment with the same
concentration range for 3 days prior to supplement withdrawal (D) is less
disruptive of neurogenesis; there is a dose-related trend in suppressed
neuroblast formation, but only the highest dose (3µM) causes a statistically
significant reduction. One-Way ANOVA, Dunnet’s Multiple Comparison Test
of significance; N = 3 for all groups; ∗p < 0.05; ∗∗p < 0.01. Error bars
represent standard deviation.
BrdU+ cells in both the dentate gyrus and the SEZ, although
only the difference for the SEZ reaches statistical significance
compared to controls (Figure 7D).
In Utero AZT Administration Perturbs NSPC
Proliferation and Neurogenesis
We next investigated whether in utero exposure to AZT perturbs
prenatal and early postnatal neurogenesis, AZT (250mg/kg/day
s.q.) was administered to pregnant females/dams between day 12
of gestation and postnatal day 3 (P3). This dosing regimen was
chosen to correspond to the current clinical approach to treating
pregnant, HIV-positive women in an attempt to prevent vertical
(mother-to-child) transmission of infection. We found no sig-
nificant differences in litter size, pup weight, or weight of the
dams between control and AZT-treated groups (data not shown).
In order to assess the effect of in utero AZT on neurogenic
stem/progenitor cell expansion, primary MASC were generated
from the offspring on P3. Our results show that in utero AZT
administration is associated with decreased expansion poten-
tial of primary (passage 0) MASC derived from offspring SEZ
(Figure 8A). As can be seen from this graphical representa-
tion, AZT-treated and control MASC equilibrate at passage 1,
and do not show statistically significant differences in expansion
potential through passage 6, the last passage analyzed.
We additionally examined the effect of in utero AZT on
inducible neurogenesis from MASC. Passage 2 MASC derived
from P3 treated and control SEZ were induced by withdrawal of
serum and growth factors. Forty-eight hours later cells were fixed
and immunolabeled for B-III-tubulin+ neuroblasts. We find that
in utero AZT significantly decreases the inducible neurogenesis
potential of MASC cells (Figure 8B). The data show an approx-
imate 30% reduction in mean neuroblast production in AZT-
treated animals as compared to untreated controls (compare tan
and black bars in 8 B).
Finally, in order to determine if in utero AZT exposure alters
the growth potential of NS-forming cell progeny, we isolated and
plated primary SEZ dissociates from the offspring at P3. After
culturing for 10 days NS were quantified and measured. Our
results show that NS frequency does not differ between AZT-
treated pups and untreated control pups (Figure 9A). However,
as we saw with NS-forming cells treated with AZT in vitro, there
is a difference in the distribution of NS sizes (Figure 9B). Sig-
nificantly fewer large diameter NS (>120µM) are derived from
AZT-treated pups, but this is offset by a corresponding increase
in small and medium diameter NS (40–120µM).
Discussion
We have examined the effect of AZT on the biology of NSCs
and NPCs. Using both in vitro and in vivo models we found that
AZT administration is associated with severe perturbations in
both proliferative capacity and neurogenesis. These findings are
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FIGURE 6 | AZT-treated cells upregulate senescence-associated beta
galactosidase (SA-B-Gal). Neurosphere-forming cells were treated with a
single pulse of AZT (30µM) 24 h after plating. Subsequent neurospheres
were dissociated and the cells were processed for SA-B-Gal histochemistry.
(A) Untreated control neurosphere cells show low levels of SA-B-Gal activity
as compared to AZT-treated neurosphere cells (B). Graphical representation
of the quantitative results (C) shows that SA-B-Gal labeling is approximately
15-fold higher in AZT-treated cells (2% of total control cells vs. 33% of total
treated cells; unpaired t-test, p < 0.05). Similar results were obtained with
MASC exposed to a single 48 h. pulse of either 0.3 or 30µM AZT. In this
case, untreated control astrocytes (D) show a higher baseline level of
SA-B-Gal labeling than dissociated neurospheres, but the AZT-treated
astrocytes (E) show a clear and substantial upregulation of this senescence
marker. Graphical data for astroctyes (F) shows that 0.3 and 30µM AZT for
48 h. (green bars) cause a respective 50 and 75% increase in SA-B-Gal+
cells (One-Way ANOVA, Dunnett’s multiple comparison test of significance,
p < 0.01). However, 24 h. exposure (gray bars) to these concentrations does
not significantly alter SA-B-Gal expression. Asterisks indicate values
significantly different from control; error bars represent standard deviation.
N = 3 for all groups; error bars represent standard deviation.
somewhat surprising, given the general understanding of AZT’s
limited penetration into the brain parenchyma, and they may
have clinical implications pertaining to cognitive deficits in per-
sons receiving antiretroviral therapy. ThoughAZT has previously
been shown to accumulate within the superficial periventricular
regions of the brain [40], surprisingly, little attention has been
paid to potential AZT toxicities involving NSC and NPCs that
have been localized to these areas.
AZT is classified as having a high rank of CNS penetration—
effectiveness (CPE) based upon its chemical features and mea-
sured CSF concentrations (Wu et al., 1998; Kearney and Aweeka,
1999; Letendre et al., 2008; Im et al., 2009). However, there is evi-
dence showing that AZT is poorly distributed to the brain due to
the fact that it is not actively transported across the blood-brain
barrier (BBB), but relies on diffusional processes for penetration
(Thomas and Segal, 1997). The BBB is formed by cerebral blood
vessel endothelial cells in concert with astrocyte endfeet, and cre-
ates a barrier between blood and the brain parenchyma. Simi-
larly, the BBB and the BCSFB -formed by blood vessels within
choroid plexuses of the lateral, third, and fourth ventricles- play
an important role in distribution of AZT to the brain. While
passive diffusion of AZT through the BBB and BCSFB is a
relatively slow process (Thomas and Segal, 1997; Kearney and
Aweeka, 1999; Cysique et al., 2004; Evers et al., 2004; Letendre
et al., 2004), AZT is rapidly removed from the brain via an
active probenecid-sensitive transport eﬄux (Dykstra et al., 1993;
Takasawa et al., 1997a,b; Sawchuk and Yang, 1999). For these
reasons there is significant pessimism regarding the therapeutic
efficacy of AZT in the treatment of central manifestations of HIV
infection (Groothuis and Levy, 1997).
HIV infection in the CNS leads to the development of
asymptomatic neurocognitive impairment, HIV-associated mild
neurocognitive disorder (MND), and AIDS dementia complex
(ADC) or HIV associated dementia (HAD) with impairment
in cognitive activity, memory, attention, and motor and behav-
ioral functioning (Antinori et al., 2007). Therefore prevention
of HIV infection in the CNS is a major clinical goal. In order
to enhance levels of antiretroviral drugs including AZT in CNS
and tomake themmore efficient, researchers focus on developing
new strategies such as intranasal administration of AZT, develop-
ing BBB-permeable derivatives of antiretroviral drugs and eﬄux
inhibitors, and modulating transporters (Zhikova and Stankova,
2000; Eilers et al., 2008; Miller et al., 2008; Quevedo et al., 2008;
Im et al., 2009; Li et al., 2010; Saiyed et al., 2010). On the other
hand, the potential effects of direct exposure of excessive AZT
concentrations and immune response to the toxicity on the CNS
are not known. We suggest that in the case of increased long-
term delivery of AZT into the brain, a direct exposure to the
CNS would cause more dramatic changes than we have shown
in our short-term in vitro and in vivo assays. Indeed, it has been
reported that antiretroviral drugs with good CNS penetration are
associated with poor neurocognitive performance of advanced
HIV patients (Marra et al., 2009). We believe that the superfi-
cial location of the neurogenic niches with respect to the ven-
tricular spaces, and the unique cytoarchitecture of the SEZ stem
cells, which contact both the lateral ventricle and cerebral blood
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FIGURE 7 | AZT reduces SEZ but not hippocampal neurogenesis
in vivo. Adult mice received a 2-week regimen of AZT (20 or
100mg/kg/day, i.p.). On the day after the last AZT injection, animals
received 4 successive injections of BrdU (100mg/kg) at 2-h intervals.
One week later the animals were euthanized and the brains were
processed and analyzed. Representative epifluorescence images of
coronal sections through the hippocampal dentate gyrus (A) and SEZ
(C) of the adult mouse immunolabeled for BrdU (green) and NeuN
(red). Inset in (A) shows two BrdU+ (green) cells in the molecular
layer of the dentate gyrus, immediately superficial to the subgranular
zone.Neither the 20mg/kg/day (B) nor the 100mg/kg/day (D) regimen
significantly altered the number of newly-generated cells (green) in the
dentate gyrus (gray bars in both B,D). However, both regimens
reduced proliferation in the SEZ (blue bars in B, black bars in D),
though only the 100mg/kg AZT dose reached statistical significance.
Unpaired Student’s t-test. NS, no significant difference. Asterisk
indicates significant difference, p < 0.01. N = 4 for all groups. Error
bars represent standard deviation.
vessels, exposes neural stem cells to high levels of circulating
AZT.
The present results show that AZT reduces the prolifera-
tive capacity of exposed cells, both in vitro and in vivo. Our
culture assays of MASC, NS, and NCFC all show attenuated
population expansion that is accompanied by a concomitant
increase in senescence-associated beta galactosidase activity.
Likewise, MASC, and NS derived from the brains of animals
exposed in utero to AZT show similar impairments in prolif-
eration when compared to untreated controls. In addition to
suppressing proliferative capacity, AZT also clearly inhibits the
capacity for NSPCs to generate new neuroblasts. In vitro, this
effect is seen using a model of inducible neurogenesis from
MASC cultures derived from the SEZ. This action occurs rel-
atively quickly, as it requires AZT to be present at the ini-
tiation of induction. To examine whether in vivo exposure
of AZT disrupts proliferation within adult neurogenic zones,
we injected adult animals with AZT at clinically relevant low
(20mg/kg/day) and moderate (100mg/kg/day) concentrations
for a short time period (2 weeks). Proliferation was assessed by
BrdU incorporation within the dentate gyrus and SEZ. These
analyses reveal that the low dose does not perturb prolifera-
tion in either the dentate gyrus or the SEZ. However, the mod-
erate dose initiated a decline of proliferation in both of the
regions. It seems, then that both of these neurogenic niches are
potentially susceptible to systemically-administered AZT, and
the will likely show more dramatic impairments with a longer
treatment regimen that is more similar to the human thera-
peutic condition. We also examined whether perinatal expo-
sure of AZT perturbs prenatal and early postnatal neurogenesis.
Dams were treated with 250mg/kg/day of subcutaneous AZT
from day 12 of gestation until postnatal day 3, mimicking the
treatment regimen recommended for pregnant HIV+ women.
This treatment paradigm was not overtly toxic, as the litter sizes
and pup weights were not significantly different from controls
(data not shown). However, inducible neurogenesis was reduced
by about 30% in MASC cultures derived from treated pup
brains.
The mechanistic causes of the negative sequelae related to
AZT exposure are beyond the scomp of our present report. How-
ever, there are four recognized, direct mechanisms by which AZT
might exert a toxic effect on normal cells, and it is possible that
synergistic combinations of these mechanisms account for the
clinical side effects of AZT therapy. First, it may be that the origi-
nal ID50 reports for AZT, obtained with the cancerous H9 T-cell
line, do not translate accurately to other cell types. In fact, subse-
quent investigations have revealed radically lower ID50 values for
cell proliferation than were originally described in the study by
Furman et al. (1986) suggesting that, at therapeutically prescribed
dosages, DNA polymerase α does incorporate triphosphorylated
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FIGURE 8 | In utero AZT perturbs MASC proliferation and
differentiation. AZT was administered to pregnant dams from day 12 of
gestation until postnatal day 3 (250mg/kg/day, s.q.). At postnatal day 3
primary MASC were generated from the SEZ of the pups. The MASC were
assayed for inducible neurogenesis at passage 1, and were assayed for
population expansion over 6 passages. (A) In utero AZT administration also
decreases the expansion potential of primary MASC, but this deficit is not
maintained over 6 passages as control and treated MASC equilibrate in
population expansion after passaging. (B) Inducible neurogenesis in MASC
cultures derived from pups exposed to AZT in utero is reduced by
approximately 35% compared to age-matched pups born to untreated
mothers. Unpaired Student’s t-test; N = 3 for all groups; ∗p < 0.05.Error bars
represent standard deviation.
AZT into cellular DNA chains during replication (Inoue et al.,
1989; Mansuri et al., 1990). Additionally, while there is a 100-fold
selectiveness of AZT for viral RT over DNA polymerase α, the
fact that the human genome is approximately 3×105 times larger
than the HIV genome means that there is still a high probability
of AZT inserting into—and terminating—cellular DNA chains
during each round of cell division (Chiu and Duesberg, 1995).
Second, while RT has a greater affinity for AZT than do the
cellular DNA polymerases responsible for normal chromosomal
replication, there are other polymerases within eukaryotic cells
that might also incorporate AZT. For instance, polymerase γ
(gamma)—the enzyme responsible for the replication and main-
tenance of the mitochondrial genome—also incorporates nucleo-
side analogs efficiently (Lee et al., 2003). The pathological effects
of such incorporation might include the loss of mitochondrial
FIGURE 9 | In utero AZT reduces neurosphere size. AZT was
administered to pregnant dams from day 12 of gestation until postnatal day 3
(250mg/kg/day, s.q.). Single-cell dissociates of SEZ were prepared from pup
brains on postnatal day 3 and assayed for neurosphere production. (A) The
total number of neurospheres generated from AZT-treated vs.control pups
does not differ. (B) While total neuroshere number does not difffer between
treated and control groups, In utero AZT causes a clear and significant
reduction in the diameter of neurospheres generated from the pups of treated
mothers as compared to the pups of untreated control mothers; notice the
reduction in the the number of large diameter neurospheres (>120µM) and a
corresponding increase in the number of small and medium diameter
neurospheres (40–120µM) in the the treated group as compared to the
controls. Unpaired Student’s t-test for (A); One-Way ANOVA for (B) N = 3 for
all groups; ∗p < 0.05. Error bars represent standard deviation.
DNA and/or severe oxidative stress (Lewis, 2003), which would
account for some of the symptomology associated with antiretro-
viral therapy. Indeed, both in vitro and in vivo studies have
consistently revealed deleterious effects of AZT on oxidative
phosphorylation (Hobbs et al., 1995) and mtDNA synthesis
(Simpson et al., 1989). Perturbations of mitochondrial DNA
polymerase γ may underlie such dysfunctions, as shown by
Lewis et al. (1994), who demonstrated that AZT-triphosphate
(TP) inhibits bovine polymerase γ through both competitive and
non-competitive mechanisms.
Third, AZT may perturb the phosphorylation of
naturally-occurring, intracellular nucleotide pools. While
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both the naturally-occurring and synthetic nucleosides must
undergo intracellular tri-phosphorylation before they can be
incorporated into DNA chains, not all nucleosides are phospho-
rylated with the same efficiency. There is evidence that in vivo
tri-phosphorylation of AZT is very inefficient; however, AZT is
abundantly mono- and di-phosphorylated, and accumulations
of AZT-MP and AZT-DP can perturb normal thymine phospho-
rylation (see Papadopulos-Eleopulos et al., 1999 for a review).
For example, it has been shown that rat cardiac mitochondria,
can process AZT only to the monophosphorylated form, and
accumulation of AZT-MP acts as a competitive inhibitor of
subsequent thymine phosphorylation (McKee et al., 2004). In
fact, in the original AZT toxicity study in vitro phosphorylation
kinetics showed that the presence of AZT leads to a massive
intracellular decrease in triphosphorylated forms of thymidine,
cytidine, and guanosine, while triphosphorylated adenosine is
increased (Nakashima et al., 1986). It is likely that such patho-
logical intracellular processing characteristics of AZT underlie
some of the toxic effects of antiretroviral therapy.
Fourth, AZT might exhibit a direct toxic effect through
disruption of telomerase activity, leading to shortened telom-
eres. Telomeres are repeating TTAGGG sequences that cap
the ends of chromosomes, and are believed to protect against
end-to-end chromosome fusion. Since DNA polymerase cannot
completely replicate linear DNA strands, telomeres grow pro-
gressively shorter with each cell division in most somatic cells.
However, highly proliferative cells such as germline cells, can-
cer cells, and stem and progenitor cells maintain telomere length
during mitosis via the activity of telomerase (Singer and Berg,
1990). Telomerase is a ribonucleoprotein that maintains telom-
ere length by adding telomere repeats to the 3′ end of DNA
strands after cell division. This is accomplished by the reverse
transcription of its AAUCCC RNA sequences into TTAGGG
DNA sequences, and their attachment to the ends of chromo-
somes. Telomerase, therefore, is a reverse transcriptase that, like
HIV RT, may be a target for AZT-mediated chain termination.
If this is the case, there is reason to believe that neurogenesis
and neural differentiation will be adversely affected. Caporaso
et al. (2003) showed in vivo that telomerase activity is absent
from most of the adult rodent brain, but that high activity is
maintained in the germinal niches that are responsible for per-
sistent neurogenesis. In vitro studies, too, have shown that AZT-
mediated telomerase perturbation leads to reduced proliferation
of embryonic mouse cortical neuronal precursor cells (Haik et al.,
2000). Finally, knockout mice (Terc−/−), that are telomerase
deficient due to a deletion in the telomerase RNA component,
show telomere attrition that is linked to perturbation of both
proliferation and differentiation of adult neural stem cells (Ferron
et al., 2004, 2009).
Finally, since our results suggest that AZT impairs pro-
liferation, it may be that AZT perturbs growth through the
induction of senescence pathways. Recently, we have reported
that senescence is induced by the uptake of the non-chain-
terminating thymidine analogs, bromodeoxyuridine (BrdU), and
ethynyldeoxyuridine (EdU). Specifically, incorporation of these
analogs leads to suppressed proliferation among treated cells
and their progeny (Levkoff et al., 2008; Ross et al., 2008, 2011).
Senescence induction may be a property of the larger family of
synthetic thymidine analogs, including AZT. While the mech-
anism behind thymidine analog-induced senescence has so far
remained enigmatic, there are a number of plausible mechanisms
that may be involved. These include perturbation of nucleoside
phosphorylation kinetics, telomerase inhibition, and mitochon-
drial dysfunction. Alternatively, an as-yet unidentified mecha-
nism may be responsible for the senescent phenotype. Recent
proteomic work by Ukekawa et al. (2007) shows that lamin A/C
and pre-lamin A are the most abundantly upregulated proteins
in both senescing normal human fibroblasts and HeLa cells that
had been exposed to BrdU. Additionally, they found that mRNA
coding for Zmpste 24 (FACE-1), the enzyme responsible for pro-
teolytic cleavage of the pre-lamin A CAAX motif, was severely
reduced in both senescing fibroblasts and HeLa cells after expo-
sure to BrdU. Since mutation of the lamin A gene has been
causally linked to the senescence human phenotype, Hutchinson-
Guilford progeria (Eriksson et al., 2003), it seems reasonable to
suspect that thymidine analog disruption of the nuclear envelope
underlies the senescence of cells exposed to BrdU and AZT.
Together, our data reveal uncharacterized negative conse-
quences of AZT treatment on neural stem and progenitor cells.
Most of the toxic effects of AZT in humans occur after long time
scales, beyond the capability of our in in vivo experiments with
short-term treatment models. The long-term use of AZT as a
part of anti-HIV therapy seems likely to affect NSPCs within the
adult brain. Given the fact that HIV infection leads to develop-
ment of neurological deficits and that human HIV+ patients are
treated with AZT over multiple years, it is important to deter-
mine to what extent AZT regimens might perturb normal levels
of neurogenesis to exacerbate or contribute to these neurological
problems.
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